Exciva Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $69.8M

  • Investors
  • 10

Exciva General Information

Description

Developer of an antitussive medication designed to address both the neurological and psychological aspects of behavioral and psychological symptoms. The company specializes in developing disease-modifying therapies, cures, prophylactics, supplements, formulations, and methods for making and using such compositions, enabling the healthcare industry to access its program for rescuing and repurposing approved drugs for new indications and uses.

Contact Information

Website
www.exciva.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Hauptstraße 25
  • 69117 Heidelberg
  • Germany
+49 06221
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Hauptstraße 25
  • 69117 Heidelberg
  • Germany
+49 06221

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Exciva Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 20-Jan-2026 $69.8M Completed Clinical Trials - Phase 2
2. Later Stage VC (Series A) 26-Oct-2021 Completed Clinical Trials - Phase 1
1. Early Stage VC 01-Jan-2019 Completed Generating Revenue
To view Exciva’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Exciva Patents

Exciva Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026156036-A1 Compositions and methods for enhancing deramciclane therapeutic concentration Pending 14-Jan-2025
WO-2026156077-A2 Compositions and methods for modulating plasma levels of brain-derived neurotrophic factor Pending 14-Jan-2025
WO-2026156077-A3 Compositions and methods for modulating plasma levels of brain-derived neurotrophic factor Pending 14-Jan-2025
CA-3062452-A1 Compositions, combinations, and methods thereof for treatment of neurological disorders Active 04-May-2017
CA-3062452-C Compositions, combinations, and methods thereof for treatment of neurological disorders Active 04-May-2017 A61P25/00
To view Exciva’s complete patent history, request access »

Exciva Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Exciva Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
CARMA FUND Management Venture Capital Minority
Dolby Family Ventures Venture Capital Minority
EQT Life Sciences Venture Capital Minority
Fountain Healthcare Partners Venture Capital Minority
Gimv PE/Buyout Minority
You’re viewing 5 of 10 investors. Get the full list »

Exciva FAQs

  • When was Exciva founded?

    Exciva was founded in 2015.

  • Where is Exciva headquartered?

    Exciva is headquartered in Heidelberg, Germany.

  • What is the size of Exciva?

    Exciva has 5 total employees.

  • What industry is Exciva in?

    Exciva’s primary industry is Drug Discovery.

  • Is Exciva a private or public company?

    Exciva is a Private company.

  • What is Exciva’s current revenue?

    The current revenue for Exciva is .

  • How much funding has Exciva raised over time?

    Exciva has raised $80.3M.

  • Who are Exciva’s investors?

    CARMA FUND Management, Dolby Family Ventures, EQT Life Sciences, Fountain Healthcare Partners, and Gimv are 5 of 10 investors who have invested in Exciva.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process